Research update DanCann

Analysis DanCann Pharma Q1 2021: Good news flow increases fair value

3 Jun 2021

Read the full report here:

Update DanCann Pharma Q1 2021, 03 June 2021


DanCann presented investments above our expectations during the first quarter of 2021. This also means that the company is better prepared to serve the market. As important, several events occurred after the end of the first quarter. BIOTECH PHARM1 began operations, a distribution agreement was signed with Tetra Pharma and the pilot programme was extended. The positive news flow has reduced uncertainty. We raise our view on fair value per share to DKK 7.0 (6.5) for the upcoming 6-12 months.

Financial development

DanCann is still in a pre-commercial phase and had no revenues booked in the first quarter of 2021. Costs were slightly higher than expected as the EBITDA-result amounted to DKK -2.5m. The EBIT-result was DKK -2,6m. Cash flow of DKK -8.6m was lower than expected mainly due to higher investments in BIOTECH PHARM1 and in intangible assets. However, much of the full year’s need for investments should have been taken.

Progressing towards commercialization

On the other side, news flow has been good. DanCann opened its production facility BIOTECH PHARM1 in April 2021. Test production has been initiated, which should lead to a GMP certification at the end of this year after which the bulk-products can be sold on an international market. The facility will focus on rare cannabinoids, which should command a higher price than plants with high content of only THC or CBD. Another important event was the conversion of the LOI with Tetra Pharma into an distribution agreement. This agreement has great potential as it gives DanCann the exclusive rights of distribution of Reduvo Adversa® and Qixleef™ on the Nordic market as well as on the large and relatively well-established German market.

In addition, an important decision was taken by the Danish government: to extend the pilot programme by four years and to allow cannabis production permanently. The regulatory risk for DanCann has consequently been drastically reduced, as it will be possible to maintain production in Denmark for the future no matter what the conclusion of the pilot programme will be.

Valuation

Given the relatively high level of uncertainty, our assumed sales curves (and associated variable costs) from the various business models have been risk adjusted with probabilities. As the distribution agreement with Tetra Pharma is now in place, previous uncertainty related to this has been eliminated. Thus, we have increased the probabilities for the assumed sales curve from the collaboration to 32 percent from previously 26 percent. Given DMA’s decision, we have also marginally reduced the discount rate. However, we have also increased future investments. All in all, we raise the risk adjusted fair value to DKK 7.0 (6.5) for the upcoming 6-12 months, using a multiple valuation combined with a DCF-model.


Disclaimer

Carlsquare AB, www.carlsquare.se, hereinafter referred to as Carlsquare, conducts business with regard to Corporate Finance and Equity Research in which areas it, among other things, publishes information about companies including analyses. The information has been compiled from sources that Carlsquare considers to be reliable. However, Carlsquare cannot guarantee the accuracy of the information. Nothing written in the analysis should be regarded as a recommendation or invitation to invest in any financial instrument, option or the like. Opinions and conclusions expressed in the analysis are intended only for the recipient.

The content may not be copied, reproduced or distributed to another person without the written approval of Carlsquare. Carlsquare shall not be held responsible for any direct or indirect damage caused by decisions made on the basis of information contained in this analysis. Investments in financial instruments provide opportunities for value increases and profits. All such investments are also subject to risks. Risks vary between different types of financial instruments and combinations of these. Historical returns should not be considered as an indication of future returns.

The analysis is not directed to U.S. persons (as defined in Regulation S of the United States Securities Act and interpreted in the United States Investment Company Act 1940) nor may it be disseminated to such persons. The analysis is also not directed to such natural and legal persons where the distribution of the analysis to such persons would result in or entail a risk of a violation of Swedish or foreign law or constitution.

The analysis is a so-called Commissioned Research Report where the analysed Company has signed an agreement with Carlsquare for analysis coverage. The analyses are published on an ongoing basis during the contract period and for a usual fixed remuneration.

Carlsquare may or may not have a financial interest in the subject of this analysis. Carlsquare values the assurance of objectivity and independence and has established procedures for managing conflicts of interest for this purpose.

The analysts Jonatan Andersson, Markus Augustsson, Richard Ramanius and Ulf Boberg do not own and are not allowed to own shares in the company analysed.

Team

Picture of Jessica Algner
Jessica Algner

Assistant

Telephone: +49 30 809 33 47-12

LinkedIn

@

Picture of Polina Amini
Polina Amini

Senior Associate

Telephone: +49 40 300 836-14

LinkedIn

@

Picture of Markus Augustsson
Markus Augustsson

Head of Equity Research

Telephone: +46 76 235 03 20

LinkedIn

@

Picture of Agata Barsallo
Agata Barsallo

Office Management & Accounting

Telephone: +44 20 8017 6020

@

Picture of Caroline Berglund
Caroline Berglund

Head of Equity Sales

Telephone: +46 73 382 10 82

LinkedIn

@

Picture of Anders Bo
Anders Bo

Managing Partner

Telephone: +45 4199 8252

LinkedIn

@

Picture of Ulf Boberg
Ulf Boberg

Senior Advisor Life Sciences

Telephone: +46 73 312 44 90

LinkedIn

@

Picture of Manfred Drax
Manfred Drax

Partner

Telephone: +49 89 255 49 53-15

LinkedIn

@

Picture of Germar Ebner
Germar Ebner

Associate

Telephone: +49 40 300 836-26

LinkedIn

@

Picture of Anders Elgemyr
Anders Elgemyr

Managing Partner

Telephone: +46 70 496 18 15

LinkedIn

@

Picture of Maximilian Fidel
Maximilian Fidel

Associate

Telephone: +49 89 255 49 53 24

@

Picture of Sebastian Fischer
Sebastian Fischer

Director

Telephone: +49 89 255 49 53-12

LinkedIn

@

Picture of Daniel Garlipp
Daniel Garlipp

Managing Partner

Telephone: +49 40 300 836-19

LinkedIn

@

Picture of Philip Goldhahn
Philip Goldhahn

Vice President

Telephone: +49 40 300 836-21

LinkedIn

@

Picture of Thorsten Grandt
Thorsten Grandt

Vice President

Telephone: +49 30 809 33 47-20

LinkedIn

@

Picture of Johan Heigard
Johan Heigard

Vice President

Telephone: +46 70 246 99 88

LinkedIn

@

Picture of Caroline Heintz
Caroline Heintz

Associate

Telephone: +46 707 40 68 58

@

Picture of Maurice Hinrichs
Maurice Hinrichs

Associate

Telephone: +49 40 300 836-20

LinkedIn

@

Picture of Arnold Holle
Arnold Holle

Managing Partner

Telephone: +44 20 80176020

LinkedIn

@

Picture of Lars Johansen
Lars Johansen

IT&Telecom Expert

@

Picture of Elaine Kelly
Elaine Kelly

Head of Marketing

Telephone: +49 40 300 836 18

LinkedIn

@

Picture of Anna-Lena Kickbusch
Anna-Lena Kickbusch

Office Management & Accounting

Telephone: +49 40 300 836 10

LinkedIn

@

Picture of Morten Kjærulff
Morten Kjærulff

Partner

Telephone: +45 2634 9031

LinkedIn

@

Picture of Mischa Krause
Mischa Krause

Director

Telephone: +49 40 300 836-24

LinkedIn

@

Picture of Steffen Leckert
Steffen Leckert

Managing Partner

Telephone: +49 89 255 49 53 26

LinkedIn

@

Picture of Malve Liebig
Malve Liebig

Senior Associate

Telephone: +49 89 255 49 53-18

LinkedIn

@

Picture of Erik Lundberg
Erik Lundberg

Director

Telephone: +46 73 850 35 59

LinkedIn

@

Picture of Eva Macha
Eva Macha

Office Management & PA to Michael Moritz

Telephone: +49 30 809 33 47-10

LinkedIn

@

Picture of Mandy May
Mandy May

Head of Operations

Telephone: +49 30 809 33 47 16

LinkedIn

@

Picture of Mirja Meyer
Mirja Meyer

Office Management & Accounting

Telephone: +49 40 300 836 10

@

Picture of Mark Miller
Mark Miller

Managing Partner

Telephone: +49 40 300 836-11

LinkedInXING

@

Picture of Michael Moritz
Michael Moritz

Managing Partner

Telephone: +49 30 809 33 47-13

LinkedIn

@

Picture of Bertil Nilsson
Bertil Nilsson

Senior Equity Analyst

Telephone: +46 70 434 90 03

LinkedIn

@

Picture of Flemming C. Pedersen
Flemming C. Pedersen

Managing Partner

Telephone: +45 4199 8251

LinkedIn

@

Picture of Richard Ramanius
Richard Ramanius

Associate Equity Analyst

Telephone: +46 73 539 66 99

LinkedIn

@

Picture of Anika Schaefer
Anika Schaefer

Office Management & HR

Telephone: +49 89 255 495 310

@

Picture of Alexander Schleppegrel
Alexander Schleppegrel

Associate

Telephone: +45 2621 0543

LinkedIn

@

Picture of Nico Schmidt-Weidemann
Nico Schmidt-Weidemann

Partner

Telephone: +49 89 255 49 53-17

@

Picture of Caspar Graf Stauffenberg
Caspar Graf Stauffenberg

Managing Partner

Telephone: +49 89 255 49 53-11

LinkedIn

@

Picture of Gregor Steins
Gregor Steins

Associate

Telephone: +49 40 300 836-15

LinkedIn

@

Picture of Jon Tingling
Jon Tingling

Associate

Telephone: +44 77 1347-8286

LinkedIn

@

Picture of Sybille de Vegvar
Sybille de Vegvar

Business Development & Marketing

Telephone: +44 20 8017 6017

@

Picture of Oskar Wollert
Oskar Wollert

Vice President

Telephone: +46 761 71 11 60

@

Picture of Nils Zettelmeyer
Nils Zettelmeyer

Director

Telephone: +49 30 809 33 47-25

LinkedIn

@

Picture of Andreas Zetzsche
Andreas Zetzsche

Partner

Telephone: +49 30 809 3347 33

@

Picture of Gerrit Zwarg
Gerrit Zwarg

Senior Associate

Telephone: +49 40 300 836-28

LinkedIn

@